{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:56:21Z","timestamp":1790657781341,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03691-4","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:53:09Z","timestamp":1783569189000},"page":"4473-4491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Qualitative Evaluation of Fatigue and Pruritus Among Patients with Primary Biliary Cholangitis"],"prefix":"10.1007","volume":"43","author":[{"given":"Cynthia","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Ginchereau Sowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine A.","family":"B\u00f6ing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"1","key":"3691_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145\u201372.","journal-title":"J Hepatol"},{"key":"3691_CR2","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.3390\/cells10081917","volume":"10","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Kar A, Khatun N, Datta P, Biswas A, Barik S. Familiarity breeds strategy: in silico untangling of the molecular complexity on course of autoimmune liver disease-to-hepatocellular carcinoma transition predicts novel transcriptional signatures. Cells. 2021;10:1917.","journal-title":"Cells"},{"issue":"1","key":"3691_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394\u2013419.","journal-title":"Hepatology"},{"issue":"6","key":"3691_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000179","volume":"7","author":"J Trivella","year":"2023","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7(6):e0179.","journal-title":"Hepatol Commun"},{"issue":"1","key":"3691_CR5","first-page":"49","volume":"8","author":"A Galoosian","year":"2020","unstructured":"Galoosian A, Hanlon C, Zhang J, Holt EW, Yimam KK. Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches. J Clin Transl Hepatol. 2020;8(1):49\u201360.","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"3691_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1111\/jgh.15329","volume":"36","author":"T Lv","year":"2021","unstructured":"Lv T, Chen S, Li M, Zhang D, Kong Y, Jia J. Regional variation and temporal trend of primary biliary cholangitis epidemiology: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2021;36(6):1423\u201334.","journal-title":"J Gastroenterol Hepatol"},{"key":"3691_CR7","unstructured":"Buchanan-Peart K-A, Macewan JP, Levine A, et al. United States (US) Prevalence of diagnosed primary biliary cholangitis: 41 per 100,000 adults with wide regional variability. AASLD The Liver Meeting 2024. Boston, MA, USA; 2024."},{"issue":"4","key":"3691_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3350\/cmh.2012.18.4.375","volume":"18","author":"HE Jung","year":"2012","unstructured":"Jung HE, Jang JY, Jeong SW, et al. Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score. Clin Mol Hepatol. 2012;18(4):375\u201382.","journal-title":"Clin Mol Hepatol"},{"issue":"3","key":"3691_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/j.1572-0241.2006.00423.x","volume":"101","author":"M Koulentaki","year":"2006","unstructured":"Koulentaki M, Ioannidou D, Stefanidou M, et al. Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am J Gastroenterol. 2006;101(3):541\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"3691_CR10","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1159\/000506980","volume":"38","author":"T Milovanovic","year":"2020","unstructured":"Milovanovic T, Popovic D, Stojkovic Lalosevic M, Dumic I, Dragasevic S, Milosavljevic T. Quality of life in patients with primary biliary cholangitis: a single-center experience in Serbia. Dig Dis. 2020;38(6):515\u201321.","journal-title":"Dig Dis"},{"issue":"19","key":"3691_CR11","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.3748\/wjg.v23.i19.3418","volume":"23","author":"K Tajiri","year":"2017","unstructured":"Tajiri K, Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. World J Gastroenterol. 2017;23(19):3418\u201326.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"3691_CR12","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.4254\/wjh.v14.i6.1111","volume":"14","author":"EN Lynch","year":"2022","unstructured":"Lynch EN, Campani C, Innocenti T, et al. Understanding fatigue in primary biliary cholangitis: from pathophysiology to treatment perspectives. World J Hepatol. 2022;14(6):1111\u20139.","journal-title":"World J Hepatol"},{"issue":"11","key":"3691_CR13","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1111\/jdv.17485","volume":"35","author":"M Augustin","year":"2021","unstructured":"Augustin M, Garbe C, Hagenstrom K, Petersen J, Pereira MP, Stander S. Prevalence, incidence and presence of comorbidities in patients with prurigo and pruritus in Germany: a population-based claims data analysis. J Eur Acad Dermatol Venereol. 2021;35(11):2270\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"3691_CR14","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.cgh.2020.06.062","volume":"19","author":"AJ Montano-Loza","year":"2021","unstructured":"Montano-Loza AJ, Corpechot C. Definition and management of patients with primary biliary cholangitis and an incomplete response to therapy. Clin Gastroenterol Hepatol. 2021;19(11):2241-51 e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"3691_CR15","first-page":"187","volume":"9","author":"Y Shu","year":"2021","unstructured":"Shu Y, Song Y, Bai T, et al. Predictive model of ursodeoxycholic acid treatment response in primary biliary cholangitis. J Clin Transl Hepatol. 2021;9(2):187\u201393.","journal-title":"J Clin Transl Hepatol"},{"issue":"8","key":"3691_CR16","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","volume":"16","author":"M Lu","year":"2018","unstructured":"Lu M, Zhou Y, Haller IV, et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol. 2018;16(8):1342-50 e1.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"3691_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.dld.2017.05.001","volume":"49","author":"P Invernizzi","year":"2017","unstructured":"Invernizzi P, Floreani A, Carbone M, et al. Primary biliary cholangitis: advances in management and treatment of the disease. Dig Liver Dis. 2017;49(8):841\u20136.","journal-title":"Dig Liver Dis"},{"key":"3691_CR18","unstructured":"United States Food and Drug Administration. Ocaliva label 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/207999s000lbl.pdf. Accessed Feb 2026."},{"issue":"2","key":"3691_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100248","volume":"3","author":"D D\u2019Amato","year":"2021","unstructured":"D\u2019Amato D, De Vincentis A, Malinverno F, et al. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Rep. 2021;3(2):100248.","journal-title":"JHEP Rep"},{"issue":"3","key":"3691_CR20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","volume":"68","author":"MJ Mayo","year":"2023","unstructured":"Mayo MJ, Carey E, Smith HT, et al. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis. Dig Dis Sci. 2023;68(3):995\u20131005.","journal-title":"Dig Dis Sci"},{"key":"3691_CR21","unstructured":"European Medicines Agency. EMA recommends revoking conditional marketing authorisation for Ocaliva. 2024. https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-revoking-conditional-marketing-authorisation-ocaliva. Accessed Feb 2026."},{"issue":"9","key":"3691_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795\u2013805.","journal-title":"N Engl J Med"},{"issue":"9","key":"3691_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, et al. A phase\u00a03 trial of seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390(9):783\u201394.","journal-title":"N Engl J Med"},{"issue":"8","key":"3691_CR24","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 1\u2014Eliciting Concepts for a New PRO Instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"key":"3691_CR25","unstructured":"United States Food and Drug Administration. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders. 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-selecting-developing-or-modifying-fit-purpose-clinical-outcome. Accessed June 2026."},{"issue":"6","key":"3691_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000179","volume":"7","author":"J Trivella","year":"2023","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7(6):e0179. https:\/\/doi.org\/10.1097\/HC9.0000000000000179.","journal-title":"Hepatol Commun"},{"issue":"1","key":"3691_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000216","volume":"23","author":"A Faisal","year":"2024","unstructured":"Faisal A. Understanding fatigue and pruritus in primary biliary cholangitis. Clin Liver Dis (Hoboken). 2024;23(1):e0216. https:\/\/doi.org\/10.1097\/CLD.0000000000000216.","journal-title":"Clin Liver Dis (Hoboken)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03691-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03691-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03691-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:15:15Z","timestamp":1790655315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03691-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3691"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03691-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Cynthia Levy: Received grants from Calliditas, CymaBay, Gilead, GlaxoSmithKline, Intercept, Ipsen, Kowa, Mirum, Pliant, Target RWE, and Zydus; is an associate editor for\n                      Hepatology\n                      ; Chair for the AASLD Practice Guidelines Committee. Betsy Williams: Employee of IQVIA at the time of the study. France Ginchereau Sowell: Employee of IQVIA. Julie Dietrich: Employee of Genfit at the time of the study and holds stock\/stock options with Genfit. Elaine A B\u00f6ing: Employee of Ipsen at the time of the study and holds stock\/stock options with Ipsen. Gail Wright: Is President of the Canadian PBC Society (unpaid role). J\u00f6rn M Schattenberg: Received consulting fees from Akero, Alentis, Alexion, Altimmune, Astra Zeneca, 89Bio, Boehringer Ingelheim, Gilead Sciences, GSK, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals, Kr\u00edya Therapeutics, Eli Lilly, eTherapeutics, Merck, MSD Sharp & Dohme GmbH, Novo Nordisk, and Roche; received payment or honoraria from AbbVie, Boehringer Ingelheim, Gilead Sciences, Ipsen, Lilly, Madrigal Pharmaceuticals, MSD, and Novo Nordisk; received support for attending meetings and\/or travel from Boehringer Ingelheim and Ipsen; holds stock\/stock options with Hepta Bio.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The protocol and study documents were approved by Western Institutional Review Board-Copernicus Group institutional review board (reference number 20213616). Informed consent was obtained from all individual participants whose PRO data were evaluated in the analysis.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}